Ultra-low-dose opioid antagonists to enhance opioid analgesia


  • Paul Sloan, MD
  • Scott Hamann, PhD, MD




chronic pain, opioid agonists, opioid antagonists, adjuvant analgesics, cancer pain, hyperalgesia, analgesia


This article will review decades of science contributing to current interest in opioid excitatory pharmacology. A long history of clinical confusion provided the stimulus for recent, detailed in vivo and in vitro investigations of the neuropharmacologic mechanisms involved in analgesic and hyperalgesic actions of opioid agonists and antagonists. Following the discovery of central nervous system opioid excitatory-hyperalgesic processes in animals, detailed neuronal cell culture experiments established opioid receptor/G protein/adenylate cyclase neurobiochemical mechanisms for bimodal inhibitory versus excitatory actions of opioids. Once this novel model was available to explain the cellular mechanisms responsible for the duality of opioid actions, clinical translation of this technology began to emerge, with a primary focus on selective antagonism of opioid excitatory actions with concomitant low-dose opioid antagonists. Encouraging results from recent animal and clinical studies will be discussed as further evidence that therapeutic pain management may be improved through enhancement of opioid agonist analgesia by cotreatment with ultra-low-dose opioid antagonists that selectively attenuate opioid-mediated hyperalgesia.

Author Biographies

Paul Sloan, MD

Department of Anesthesiology, University of Kentucky Medical Center, Lexington, Kentucky.

Scott Hamann, PhD, MD

Department of Anesthesiology, University of Kentucky Medical Center, Lexington, Kentucky.


Sloan PA, Moulin DE, Hays H: A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage. 1998; 16(2): 102-111.

Cherny NJ, Chang V, Frager G, et al.: Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995; 76(7): 1283-1293.

McDonnell FJ, Sloan JW, Hamann SR: Advances in cancer pain management. Curr Oncol Rep. 2000; 2(4): 351-357.

Angst MS, Clark JK: Opioid-induced hyperalgesia: A qualitative, systematic review. Anesthesiology. 2006; 104(3): 570-587.

Sloan PA, Slatkin N, Ahdieh H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer. 2005; 13(1): 57-65.

Bannwarth B: Do selective cyclo-oxygenase-2 inhibitors have a future? Drug Saf. 2005; 28(3): 183-189.

Lossignol DA, Obiols-Portis M, Body JJ: Successful use of ketamine for intractable cancer pain. Support Care Cancer. 2005; 13(3): 188-193.

Berger A, Hoffman DL, Goodman S, et al.: Therapy switching in patients receiving long-acting opioids. Ann Pharmacother. 2004; 38(3): 389-395.

Sloan PA: The evolving role of interventional pain management in oncology. J Support Oncol. 2004; 2(6): 491-500.

Cruciani RA, Lussier D, Miller-Saultz D, et al.: Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage. 2003; 25(6): 491-494.

Minami M, Satoh M: Molecular biology of the opioid receptors: Structures, functions and distributions. Neurosci Res. 1999; 23: 121-145.

Martin WR: History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol. 1979; 7 Suppl 3: 273S-279S.

Isbell H, Fraser HF: Addiction to analgesics and barbiturates. J Pharmacol Exp Ther. 1950; 99(4:2): 355-397.

Lasagna L, Beecher HK: The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J Pharmacol Exp Ther. 1954; 112(3): 356-363.

Lasagna L: Drug interaction in the field of analgesic drugs. Proc R Soc Med. 1965; 58(11 Part 2): 978-983.

Keats AS, Telford J: Nalorphine, a potent analgesic in man. J Pharmacol Exp Ther. 1956; 117(2): 190-196.

McClane TK, Martin WR: Effects of morphine, nalorphine, cyclazocine, and naloxone on the flexor reflex. Int J Neuropharmacol. 1967; 6(2): 89-98.

Levine JD, Gordon NC, Jones RT, et al.: The narcotic antagonist naloxone enhances clinical pain. Nature. 1978; 272(5656): 826-827.

Levine JD, Gordon NC, Fields L: Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature. 1979; 278(5706): 740-741.

Woolf CJ: Intracerebral naloxone and the reaction to thermal noxious stimulation in the rat. Brain Res. 1980; 190(2): 578-583.

Holaday JW, Belenky GL: Opiate-like effects of electroconvulsive shock in rats: A differential effect of naloxone on nociceptive measures. Life Sci. 1980; 27(21): 1929-1938.

Levine JD, Gordon NC: Method of administration determines the effect of naloxone on pain. Brain Res. 1986; 365(2): 377-378.

Kayan S, Woods L, Mitchell CL: Morphine-induced hyperalgesia in rats tested on the hot plate. J Pharmacol Exp Ther. 1971; 177(3): 509-513.

Jacquet YF, Lajtha A: Paradoxical effects after microinjection of morphine in the periaqueductal gray matter in the rat. Science. 1974; 185(156): 1055-1057.

Kayser V, Besson JM, Guilbaud G: Analgesia produced by low doses of the opiate antagonist naloxone in arthritic rats is reduced in morphine-tolerant animals. Brain Res. 1986; 371(1): 37-41.

Wu K, Martin WR: Effects of naloxone and fentanyl in acutely decerebrated dogs. Life Sci. 1982; 31(2): 151-157.

Wu K, Martin WR, Kammerling SG, et al.: Possible medullary kappa hyperalgesic mechanism. I. A new role for endogenous opioid peptides in pain perception. Life Sci. 1983; 33(18): 1831-1838.

Parvini S, Hamann SR, Martin WR: Pharmacologic characteristics of a medullary hyperalgesic center. J Pharmacol Exp Ther. 1993; 265(1): 286-293.

Hamann SR, Martin WR: Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem. J Pharmacol Exp Ther. 1992; 261(2): 707-715.

Hamann SR, Martin WR: Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone, and (-)-lobeline in the rat brain stem. Pharmacol Biochem Behav. 1994; 47(1): 197-201.

Bie B, Fields HL, Williams JT, et al.: Roles of alpha1- and alpha2-adrenoceptors in the nucleus raphe magnus in opioid analgesia and opioid abstinence-induced hyperalgesia. J Neurosci. 2003; 23(21): 7950-7957.

Gillman MA, Lichtigfeld FJ: A pharmacological overview of opioid mechanisms mediating analgesia and hyperalgesia. Neurol Res. 1985; 7(3): 106-119.

Gillman MA, Lichtigfeld FJ: Naloxone analgesia: An update. Int J Neurosci. 1989; 48(3-4): 321-324.

Vaccarino AL, Tasker RAR, Melzack R: Analgesia produced by normal doses of opioid antagonists alone and in combination with morphine. Pain. 1989; 36(1): 103-109.

Kayser V, Guilbaud G: Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats. Brain Res. 1981; 226(1-2): 344-348.

Arts KS, Fujimoto JM, Crain SM: Inhibition of the antianalgesic action of dynorphin A in mice by cholera toxin. Pharmacol Biochem Behav. 1993; 46(3): 623-629.

Fujimoto JM, Fady JJ: Intracerebroventricular physostigmine-induced analgesia: Enhancement by naloxone, beta-funaltrexamine and norbinaltorphimine and antagonism by dynorphin A (1-17). J Pharmacol Exp Ther. 1989; 251(3): 1045-1052.

Vanderah TW, Gardell LR, Burgess SE, et al.: Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000; 20(18): 7074-7079.

Holmes BB, Fujimoto JM: Inhibiting a spinal dynorphin A component enhances intrathecal morphine antinociception in mice. Anesth Analg. 1993; 77(6): 1166-1173.

Hamann SR, Martin WR: Analgesic actions of dynorphin A(1-13) antiserum in the rat brain stem. Brain Res Bull. 1992; 29(5): 605-607.

Ueda H, Fukushima N, Kitao T, et al.: Low doses of naloxone produce analgesia in the mouse brain by blocking presynaptic auto-inhibition of enkephalin release. Neurosci Lett. 1986; 65(3): 247-252.

Schmidt JF, Chraemmer-Jorgensen B, Pedersen JE, et al.: Postoperative pain relief with naloxone. Severe respiratory depression and pain after high-dose buprenorphine. Anaesthesia. 1985; 40(6): 583-586.

Levine JD, Gordon NC, Taiwo YO, et al.: Potentiation of pentazocine analgesia by low-dose naloxone. J Clin Invest. 1988; 82(5): 1574-1577.

Bergman SA, Wynn RL, Myers DE, et al.: Low dose naloxone enhances buprenorphine in a tooth pulp antinociceptive assay. Arch Int Pharmacodyn Ther. 1988; 291: 229-237.

Crain SM, Shen KF: Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci. 1990; 11(2): 77-81.

Crain SM, Shen KF: After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside. Brain Res. 1992; 575(1): 13-24.

Crain SM, Shen KF: After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition. J Pharmacol Exp Ther. 1992; 260(1): 182-186.

Crain SM, Shen KF: Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci U S A. 1995; 92(23): 10540-10544.

Crain SM, Shen KF: Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: New rationale for improved clinical analgesia and treatment of opiate addiction. In: Repaka RS, Sorer H (eds.): Discovery of Novel Opioid Medications, National Institute on Drug Abuse Monograph, 147. Washington, DC: US Government Printing Office, 1995, pp. 234-268.

Crain SM, Shen KF: Chronic morphine-treated sensory ganglion neurons remain supersensitive to the excitatory effects of naloxone for months after return to normal culture medium: An in vitro model of “protracted opioid dependence.” Brain Res. 1995; 694(1-2): 103-110.

Crain SM, Shen KF: Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem Res. 1996; 21(11): 1347-1351.

Crain SM, Shen KF: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists. US Patent No. 5,512,578. US Patent Office, 1996.

Crain SM, Shen KF: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally acting opioid agonists. US Patent No. 5,580,876. US Patent Office, 1996.

Crain SM, Shen KF: GM1 ganglioside-induced modulation of opioid receptor-mediated functions. Ann N Y Acad Sci. 1998; 845: 106-125.

Crain SM, Shen KF: Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci. 1998; 19(9): 358-365.

Crain SM, Shen KF: Antagonists of excitatory opioid receptor functions enhance morphine’s analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000; 84(2-3): 121-131.

Crain SM, Shen KF: Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-lowdose naltrexone, unmasking potent opioid analgesia. Brain Res. 2001; 888(1): 75-82.

Crain SM, Shen KF: Opioids can evoke direct receptor-mediated excitatory as well as inhibitory effects on sensory neuron action potentials. In Harris LS (ed.): Problems of Drug Dependence: National Institute of Drug Abuse Monograph, 105. US Government Printing Office, 1991, pp. 34-39.

Crain SM, Shen KF, Chalazonitis A: Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures. Brain Res. 1988; 455: 99-109.

Shen KF, Crain SM: Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res. 1989; 491(2): 1227-1242.

Shen KF, Crain SM: Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors. Brain Res. 1990; 525(2): 225-231.

Shen KF, Crain SM: Cholera toxin-B subunit blocks opioid excitatory effects on sensory neuron action potentials indicating that GM1 ganglioside may regulate Gs-linked opioid receptor functions. Brain Res. 1990; 531(1-2): 1-7.

Shen KF, Crain SM: Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid “dependence” without tolerance. Brain Res. 1992; 597(1): 74-83.

Shen KF, Crain SM: Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res. 1994; 636(2): 286-297.

Shen KF, Crain SM: Nerve growth factor rapidly prolongs the action potential of mature sensory ganglion neurons in culture, and this effect requires activation of Gs-coupled excitatory kappa-opioid receptors on these cells. J Neurosci. 1994; 14(9): 5570-5579.

Shen KF, Crain SM: Biphalin, an enkephalin analog with unexpectedly high antinociceptive potency and low dependence liability in vivo, selectively antagonizes excitatory opioid receptor functions of sensory neurons in culture. Brain Res. 1995; 701(1-2): 158-166.

Cruciani RA, Dvorkin B, Morris SA, et al.: Direct coupling of opioid receptors to both stimulatory and inhibitory guanine nucleotide-binding proteins in F-11 neuroblastoma-sensory neuron hybrid cells. Proc Natl Acad Sci U S A. 1993; 90(7): 3019-3023.

Shen KF, Crain SM: Ultra-low doses of naltrexone or etorphine increase morphine’s antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 1997; 757(2): 176-190.

Shen KF, Crain SM, Ledeen RW: Brief treatment of sensory ganglion neurons with GM1 ganglioside enhances the efficacy of opioid excitatory effects on the action potential. Brain Res. 1991; 559(1): 130-138.

Powell KJ, Abul-Husn NS, Jhamandas A, et al.: Paradoxical effects of opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther. 2002; 300(2): 588-596.

Cicero TJ, Nock B, Meyer ER: Gender-related differences in the antinociceptive properties of morphine. J Pharmacol Exp Ther. 1996; 279(2): 767-773.

Hamann SR, Malik H, Sloan JW, et al.: Interactions of “ultralow” doses of naltrexone and morphine in mature and young male and female rats. Receptors Channels. 2004; 10(2): 73-81.

Olmstead MC, Burns LH: Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology. 2005; 181(3): 576-581.

Wang HY, Friedman E, Olmstead MC, et al.: Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience. 2005; 135(1): 247-261.

Vanderah TW, Lai OM, Malan T, et al.: Mechanisms of opioid-induced pain and antinociceptive tolerance: Descending facilitation and spinal dynorphin. Pain. 2001; 92(1-2): 5-9.

Hamann SR, Wala EP: The effect of very low dose naltrexone on neuropathic pain in rats. FASEB Journal. 2003; 17: abstract 138.8.

Hamann SR, Hatch NW, Hicks DL, et al.: Ultra-low dose of naltrexone attenuates neuropathic but not acute pain in rats. FASEB Journal. 2004; 18: abstract 635.8.

Olmstead MC, Burns LH: Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology. 2006 (in press).

Leri F, Burns LH: Ultra-low-dose naltrexone reduces rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem and Behav. 2006 (in press).

Hamann SR, Witt WO, Sloan PA: Treatment of refractory post-lumbar laminectomy pain with ultra low-dose intrathecal morphine and naloxone. 2006 (submitted for publication).

Gan TJ, Ginsberg B, Glass PSA, et al.: Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulphate. Anesthesiology. 1997; 87(5): 1075-1081.

Joshi GP, Duffy L, Chehade J, et al.: Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology. 1999; 90(4): 1007-1011.

Sartain JB, Barry JJ, Richardson CA, et al.: Effect of combining naloxone and morphine for intravenous patient-controlled analgesia. Anesthesiology. 2003; 99(1): 148-151.

Cepeda MS, Africano JM, Manrique AM, et al.: The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain. 2002; 96(1-2): 73-79.

Maxwell LG, Kaufmann SC, Blitzer S, et al.: The effects of smalldose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patientcontrolled analgesia: A double-blind, prospective, randomized, controlled study. Anesth Analg. 2005; 100(4): 953-958.

Hamann SR, Wala EP, Rebel A, et al.: Selective antagonism of opioid excitatory receptor systems: A pilot clinical study demonstrating enhancement of morphine analgesia by lowdose naloxone in female patients undergoing elective abdominal laparotomy. American Society of Anesthesiologists Annual Meeting 2006; Abstract 387.

Chindalore VL, Craven RA, Yu KP, et al.: Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: A randomized, controlled trial of Oxytrex. J Pain. 2005; 6(6): 392-399.

Webster LR, Butera PG, Moran LV, et al. Oxytrex minimized physical dependence while providing effective analgesia: A randomized controlled trial in low-back pain. J Pain. 2006 (in press).

Hamann SR, Witt WO, Sloan PA, et al.: Pilot study for treatment of chronic pain with intrathecal morphine in combination with ultra-low dose oral naltrexone. 2006 (submitted for publication).




How to Cite

Sloan, MD, P., and S. Hamann, PhD, MD. “Ultra-Low-Dose Opioid Antagonists to Enhance Opioid Analgesia”. Journal of Opioid Management, vol. 2, no. 5, Sept. 2006, pp. 295-04, doi:10.5055/jom.2006.0044.



Review Articles